MARKET NEWS

SELLAS Life Sciences Announces Completion of Enrollment in Phase 2 Randomized Controlled Clinical Study
Opthea Confirms Final Patient Enrolment in Phase 2b Wet AMD Clinical Trial
Novo Nordisk Announces Phase 3a Results Using Emisphere’s Technology  
CBT Pharmaceuticals & Zhejiang Bossan Pharmaceutical Enter Collaboration & License Agreement
Dalton Pharma Services Enters Drug Development & Manufacturing Services Agreement
Edge Therapeutics Enters Into Merger Agreement With PDS Biotechnology

  FEATURED EDITORIAL

  COMPANY PROFILE

We are your trusted global partner for the development and supply of commercial quantities of functionalized PEGs (polyethylene glycols). Those in turn, are essential for your PEGylated therapeutic proteins for drug delivery. Our offerings include high-purity materials for use in investigational products in every phase of clinical development and in commercialized products. We understand that you care about rapid and cost-effective time to market. Therefore, setting the right quality attributes for the functionalized PEG is crucial for the manufacturing and stability of your PEGylated product — we can help you get it right. And during the marketing phase, expertise in life-cycle management and regulatory affairs can help you safeguard your compliance. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Neurelis Announces Acquisition of Leading Drug Delivery Technology Company

Neurelis Announces Acquisition of Leading Drug Delivery Technology Company

Neurelis, Inc. recently announced the acquisition of Aegis Therapeutics, a San Diego-based drug delivery technology company.

Ajinomoto Bio-Pharma Services Introduces Bioconjugation Technology for ADC Manufacturing

Ajinomoto Bio-Pharma Services Introduces Bioconjugation Technology for ADC Manufacturing

Ajinomoto Bio-Pharma Services recently presented data at the World ADC Summit in San Diego this month describing a proprietary site-selective bioconjugation technology, AJICAP.

Evelo & Merck Enter Clinical Trial Collaboration

Evelo & Merck Enter Clinical Trial Collaboration

Evelo Biosciences, Inc. recently announced it has entered into a clinical trial collaboration agreement with Merck. The collaboration will evaluate EDP1503 in combination with KEYTRUDA (pembrolizumab).

Cambrex to Acquire Avista Pharma Solutions

Cambrex to Acquire Avista Pharma Solutions

Cambrex Corporation recently announced it has entered into a definitive agreement to acquire Avista Pharma Solutions, a contract development, manufacturing, and testing organization, for approximately $252 million.

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

December 12 – Controlled Release
December 19 – Parenteral Contract Manufacturing